Strongest evidence
The most robust research on BB-12 is for reduced upper respiratory infections, where – considered moderate evidence strength based on 6 studies, 5 of which reported benefit (4 of those statistically significant). Effects were moderate on average, and one trial specified a dose of 10 billion CFU/day. This research primarily involved healthy infants and young children, though data from adults (via network meta-analysis) and children in early childhood settings also contributed. No harmful effects were reported in any study on this outcome.
Mixed or weaker evidence
Several outcomes have low or very low evidence strength due to small numbers of studies, reliance on reviews or preclinical work, and lack of statistical significance. For example:
- Increased short-chain fatty acid production (4 studies, all beneficial but mostly in vitro/ methodological, with mixed effect sizes)
- Improved intestinal barrier function (4 studies, all beneficial but mostly animal or cell models)
- Reduced antibiotic-associated diarrhea (3 studies; 2 beneficial, 1 neutral; a recent 2026 RCT found no benefit, conflicting with older positive reviews)
reviews)
- Improved gut microbiota composition (3 studies, all beneficial but small effects and limited human data)
- Reduced inflammation, improved immune function, improved gut health, and improved gastrointestinal health – each based on 3–4 studies, all reviews or preclinical work, with effect sizes ranging from small to moderate and no statistically significant primary data.
Effective dose patterns
Only one outcome — upper respiratory infections — had a reported effective dose (10 billion CFU/day from a single study). Across all other outcomes, doses were either not reported or varied too widely to identify a consistent range. No cross-cutting dose conclusion can be drawn from the available evidence.
Population insights
Most human data come from healthy infants and young children (for respiratory infections) and older adults (for short-chain fatty acid production). For outcomes like intestinal barrier function, the only human evidence comes from a systematic review in colitis patients. Many studies do not report specific population data or use animal/cell models, making it difficult to generalize to broad healthy populations.
Notable caveats
A recurring caveat across multiple syntheses is the possibility of publication bias — null results are less likely to be published, which may overstate the apparent benefits. Many studies are small, do not report doses, and rely on reviews rather than primary trials. The overall evidence base is small , and for most outcomes the conclusions are preliminary.